Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.
By G. Mingrone, S. Panunzi, Andrea De Gaetano, C. Guidone, A. Iaconelli, G. Nanni, M. Castagneto, S. Bornstein, F. Rubino. The Lancet, 2015
1,119 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics, Surgery
View Paper: https://www.semanticscholar.org/paper/ceaf308b739714b77a32aa11ee1c536ba15e9991
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nutrition and Dietetics
In Surgery
Citations in the corpus
- 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. (2022, background): “[123] Mingrone G, Panunzi S, De Gaetano A, et al.”
- Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations (2016, background): “Beyond improving glycemia, bariatric/ metabolic surgery has been shown to confer additional health benefits in RCTs, including greater reductions compared with medical/lifestyle interventions in other CVD risk factors (10–25), and enhancements in quality-of-life measures (LoE IB) (15,19,20).”
- Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers (2019, background): “Although A1C is not recommended for diagnosis of diabetes in childrenwith cystic fibrosis or symptoms suggestive of acute onset of type 1 diabetes and only A1C assays without interference are appropriate for children with hemoglobinopathies, the ADA continues to recommend A1C for diagnosis of type 2”